BOLD: Audentes Therapeutics is a Sell

The current rating for BOLD is 27, which is 85% below its historic median rating of 50. This indicates higher risk than normal.

The rating is currently showing a lower than normal reading, suggesting risk levels could be higher than normal and additional caution is advised.